Graft versus host disease

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
B Haematology (ATC B) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
BTK inhibitor 1 substance
Phase II/III: 1 Phase IV: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II/III

1 trial
  • CSL Behring LLC Commercial
    HUMAN ALPHA1-PROTEINASE INHIBITOR
    2024-511164-92-00 3 countries 2019 n=55
    Ended

Phase IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IBRUTINIB
    2023-507329-40-00 7 countries 2017 n=125
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
CSL Behring LLC Commercial 1 Phase II/III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase IV 0
New trials by year
2019
1
← All indication landscapes